TY - JOUR
T1 - Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
AU - Cohen, Calvin J.
AU - Molina, Jean Michel
AU - Cassetti, Isabel
AU - Chetchotisakd, Ploenchan
AU - Lazzarin, Adriano
AU - Orkin, Chloe
AU - Rhame, Frank
AU - Stellbrink, Hans Jürgen
AU - Li, Taisheng
AU - Crauwels, Herta
AU - Rimsky, Laurence
AU - Vanveggel, Simon
AU - Williams, Peter
AU - Boven, Katia
PY - 2013/3/27
Y1 - 2013/3/27
N2 - Background: In the week 48 primary analysis of ECHO and THRIVE, rilpivirine demonstrated noninferior efficacy and more favourable tolerability versus efavirenz in treatment-naive, HIV-1-infected adults. Pooled 96-week results are presented. Methods: Patients (N1/41368) received rilpivirine 25mg once-daily (q.d.) or efavirenz 600mg q.d., with two background nucleoside/nucleotide reverse transcriptase inhibitors, in two randomized, double-blind, double-dummy Phase III trials. Results: At week 96, response rate (% confirmed viral load
AB - Background: In the week 48 primary analysis of ECHO and THRIVE, rilpivirine demonstrated noninferior efficacy and more favourable tolerability versus efavirenz in treatment-naive, HIV-1-infected adults. Pooled 96-week results are presented. Methods: Patients (N1/41368) received rilpivirine 25mg once-daily (q.d.) or efavirenz 600mg q.d., with two background nucleoside/nucleotide reverse transcriptase inhibitors, in two randomized, double-blind, double-dummy Phase III trials. Results: At week 96, response rate (% confirmed viral load
KW - Efavirenz
KW - HIV-1
KW - Rilpivirine
KW - Treatment naive
UR - http://www.scopus.com/inward/record.url?scp=84876406278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876406278&partnerID=8YFLogxK
U2 - 10.1097/QAD.0b013e32835cee6e
DO - 10.1097/QAD.0b013e32835cee6e
M3 - Article
C2 - 23211772
AN - SCOPUS:84876406278
VL - 27
SP - 939
EP - 950
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 6
ER -